Lupin gets USFDA nod for HIV drug under PEPFAR

The product would be manufactured at the company's Nagpur-based facility.

Published: 30th June 2021 01:35 PM  |   Last Updated: 30th June 2021 01:35 PM   |  A+A-

Tablets move along the production line at a pharmaceutical plant of Lupin, India's No. 2 drugmaker, in Verna. Image used for representational purpose. (File | Reuters)


NEW DELHI: Drug maker Lupin on Wednesday said it has received approval from the US health regulator to market HIV treatment medication in the American market.

The Mumbai-based company has received tentative nod from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for its new drug application (NDA) for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) tablets (50 mg/300 mg/300 mg), along with antiretroviral fixed dose combination (FDC), Lupin said in a statement.

The product would be manufactured at the company's Nagpur-based facility, it added.

TLD tablets are recommended by the World Health Organisation (WHO), the US Agency for International Development (USAID), and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg.

"It is a significant approval for the company which has recently forayed into the HIV business arena.

We have a deep commitment to increasing access to quality and affordable treatment options for low-and-middle-income countries for decades," Lupin President (API Plus) Naresh Gupta noted.

Being integrated with in-house manufacture of active pharmaceutical ingredients (APIs) and formulations gives the company an opportunity to provide quality products and uninterrupted supplies for affordable access for patients in these countries, he added.

Lupin's current global footprint spans 11 countries, across six continents.

The company's shares were trading 0.

6 per cent down at Rs 1,154 apiece on BSE.



Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp